Connect your AI

Boston Scientific BSX Stock-Based Comp

Stock-Based Comp at other companies

AbbottABT

$317M+9.7%

TFX

TeleflexTFX

$6.74M+1.7%

Johnson & JohnsonJNJ

$300M+4.2%

StrykerSYK

$87M+3.6%

HaemoneticsHAE

$9.13M+31.6%

CONMEDCNMD

$5.5M-60.3%

Other financials

Income statement

Revenue$5.2B+11.6%

Gross profit$3.6B+12.6%

Operating income$1.1B+19.5%

Net income$1.3B+99.3%

EPS (diluted)$0.90+100%

Balance sheet

Cash & equivalents$850.0M+146%

Total debt$659.0M-94.1%

Total equity$25.9B+16.4%

Total assets$44.4B+10.5%

Cash flow

Operating cash flow$348.0M-35.7%

CapEx$177.0M-5.3%

Free cash flow$171.0M-51.7%

Valuation

Market cap$65.74B-57.3%

P/E18.5×-43.2×

P/S3.2×-5.1×

Profitability

Gross margin69.2%+0.5pp

Operating margin18.4%+2.2pp

Net margin17.3%+5.7pp

FCF margin16.9%-0.3pp

Returns & leverage

Return on equity14.8%+5.2pp

Debt / equity0×-0.5×

Current ratio1.9×+0.4×

Where this comes from

Reported directly by Boston Scientific in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: Boston Scientific’s 10-Q, filed May 1, 2026, on SEC EDGAR. View the filing →

Ask your AI about Boston Scientific's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Boston Scientific's stock-based comp?: Boston Scientific (BSX) reported stock-based comp of $83M in Q1 2026.
How has Boston Scientific's stock-based comp changed year-over-year?: Boston Scientific's stock-based comp increased by 12.2% year-over-year, from $74M to $83M.
What is the long-term trend for Boston Scientific's stock-based comp?: Over 4 years (2021 to 2025), Boston Scientific's stock-based comp has grown at a 11.4% compound annual growth rate (CAGR), from $194M to $299M.
What does stock-based comp mean?: Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.